Abvc BiopharmaABVC
13F holders, Q2 2025 (June 30)9holders −1
1new positions
2sold out
1famous investor
$2.23avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($248K), Geode Capital Management, LLC ($246K) and XTX Topco Ltd ($117K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $93K |
| Exits | 2 | $43K |
All 13F filers, Q1 2025 → Q2 2025: 130,389 shares bought and 50,509 shares sold, net +79,880 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Vanguard Group Inc. | 0.00% | Add +137.6% | 111,533 | $248K |
| Geode Capital Management, LLC | 0.00% | Add +5.8% | 110,499 | $246K |
| XTX Topco Ltd | 0.00% | Reduce -12.9% | 52,625 | $117K |
| Renaissance Technologies | 0.00% | New | 41,706 | $93K |
| Northern Trust Corp. | 0.00% | Add +94.1% | 37,144 | $83K |
| State Street Corp. | 0.00% | No change | 12,900 | $29K |
| SBI Securities Co., Ltd. | 0.00% | Add +5.0% | 483 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -86.3% | 354 | $788 |
| Bank of America Corp. | 0.00% | Add +56.5% | 133 | $296 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.